• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
AI and imaging open new avenues for studying body composition at scale

AI and imaging open new avenues for studying body composition at scale

by Truveta staff | Oct 29, 2025 | Research

Body composition is a critical factor in understanding health risk, yet it is rarely measured in routine clinical care. Instead, clinicians and researchers often rely on BMI — a measure that misses the nuance of fat distribution and its impact on outcomes like...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through September 2025 

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through September 2025 

by Truveta Research | Oct 24, 2025 | Featured post, Research, Research Insights

Respiratory virus–associated hospitalizations declined overall in September 2025 (–27.1%). COVID-associated hospitalizations declined substantially (-45.1%) but still account for the most virus-associated hospitalizations in those aged 65 and older (1.1%). Rhinovirus...
Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes

Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes

by Truveta Research | Oct 21, 2025 | Featured research, Research, Research Insights

In patients with CKD and diabetes, anemia prevalence and severity increased from stage 1 to stage 5, with overall anemia rising from 46.4% to 85.0% and severe anemia from 2.5% to 11.8% Erythropoiesis-stimulating agents (ESAs) and IV iron use rose as hemoglobin levels...
GLP-1 RA prescription trends: January 2018 – September 2025

GLP-1 RA prescription trends: January 2018 – September 2025

by Truveta Research | Oct 20, 2025 | Research, Research Insights

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in September 2025 remained stable relative to June 2025 (+4.6%). As of September 2025, GLP-1 prescriptions account for 6.5 out of every 100 prescriptions in the US. Tirzepatide continues...
Associations of nutrition counseling, insulin, and metformin therapy with post-GTT weight gain in a large pregnancy cohort

Associations of nutrition counseling, insulin, and metformin therapy with post-GTT weight gain in a large pregnancy cohort

by Truveta Research | Oct 17, 2025 | Research, Research Insights

Nearly half of patients with gestational diabetes mellitus (GDM) received nutrition counseling within 45 days of diagnosis, while smaller proportions initiated insulin (15%) or metformin (10%). Despite being the first-line intervention, about half of patients with GDM...
Real-world patterns of glucose tolerance testing and gestational diabetes in pregnancy

Real-world patterns of glucose tolerance testing and gestational diabetes in pregnancy

by Truveta Research | Oct 17, 2025 | Research, Research Insights

Nearly one-quarter of patients exceeded the 140 mg/dL threshold on the 1-hour glucose tolerance test. However, about 1 in 10 patients with elevated values did not receive recommended follow-up testing or a GDM diagnosis, highlighting gaps in adherence to clinical...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world evidence on heart failure from GLP-1 and advanced CKD populations
  • Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval
  • Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.